Effect of chemotherapy alone or combined with immunotherapy for locally advanced or metastatic genitourinary small cell carcinoma: a real-world retrospective study

BMC Cancer

Research

Xin An¹  Meiting Chen¹  Haifeng Li¹  Riqing Huang¹  Wei Yang¹  Yanxia Shi¹  Ditian Shu¹  Anqi Hu¹  Cong Xue¹  Zhiyong Li²  Yonghong Li²  Kai Yao²  Fangjian Zhou²  Zhiming Wu²  Zhuowei Liu²  Dan Sui³ 

[1] State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-Sen University Cancer Center, 510060, Guangzhou, People’s Republic of China;Department of Medical Oncology, Sun Yat-Sen University Cancer Center, Dongfeng Road East 651, 510060, Guangzhou, China;State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-Sen University Cancer Center, 510060, Guangzhou, People’s Republic of China;Department of Urology, Sun Yat-Sen University Cancer Center, Dongfeng Road East 651, 510060, Guangzhou, People’s Republic of China;The Fourth People’s Hospital of Shenyang, 110031, Shenyang, People’s Republic of China;

关键词: Genitourinary small cell carcinoma;    Metastatic;    Immunotherapy;    Chemotherapy;    Efficacy;   

DOI  :  10.1186/s12885-023-11473-2

 received in 2023-02-04, accepted in 2023-10-03,  发布年份 2023

来源: Springer

【 摘 要 】

BackgroundGenitourinary small cell carcinoma is rare, and has a poor prognosis. However, effective treatment options for this disease are limited. We present a study to assess the efficacy of chemotherapy alone or combined with immunotherapy for locally advanced or metastatic genitourinary small cell carcinoma (GSCC).MethodsWe performed a retrospective analysis of patients with locally advanced or metastatic GSCC from Jan 2013 to September 2022 at Sun Yat-sen University Cancer Center. The survival and safety profiles were analyzed.ResultsForty-two GSCC patients were enrolled, which included 20 with chemotherapy plus immunotherapy and 22 with chemotherapy alone. The median follow-up time was 15.13 months (95% CI, 8.84–21.42). The addition of immunotherapy to chemotherapy demonstrated no significant difference in median progression-free survival (p = 0.37). However, the median overall survival (OS) was 22.97 and 14.03 months with immunotherapy plus chemotherapy and chemotherapy alone, respectively (HR = 0.69, 95%CI 0.08–0.55, p = 0.017). Two patients with immunotherapy plus chemotherapy achieved clinical complete remission. The overall response rate for patients receiving chemotherapy combined with immunotherapy was 65%, which was higher in comparison to those treated with chemotherapy alone (50%). Univariate and multivariate analyses demonstrated that chemotherapy combined with immunotherapy independently achieved favorable OS. Four patients experienced immunotherapy-related adverse events, with one developing grade 3 hypothyroidism.ConclusionsAmong patients with locally advanced or metastatic GSCC, immunotherapy combined with chemotherapy might be thought of as a potentially effective treatment option for patients with GSCC.

【 授权许可】

CC BY   
© BioMed Central Ltd., part of Springer Nature 2023

【 图 表 】

Fig. 1

Fig. 4

12944_2023_1927_Article_IEq16.gif

Fig. 4

12944_2023_1927_Article_IEq7.gif

Fig. 2